Ezetimibe Plus Statin Therapy Reduces Post-ACS Cardiovascular Event Risk
Researchers evaluated the association between baseline LDL-C and treatment with ezetimibe plus statins in post-acute coronary syndrome.
Dyslipidemia
Children With Type 2 Diabetes Face Health Challenges in Adulthood
Children diagnosed with type 2 diabetes may face certain health challenges that grow worse over time and follow them into adulthood.
Pictorial Information on Vascular Age Increased Prescribing of Lipid-Lowering Drugs
A clinical trial found that more lipid-lowering medications were prescribed when physicians were provided with pictorial information of their patients’ vascular age and carotid plaques.
Metabolic Syndrome Ups Major Cardiovascular, Death Risks in CKD
Avoiding even 1 metabolic syndrome component might decrease the risk for a cardiovascular event or premature death, investigators suggest.
LDL-C Target Levels Achieved in Diabetes, But High-Intensity Statins Not Frequently Initiated
Patients with diabetes achieve LDL-C levels below recommended target goals, but high-intensity statin treatment appears frequently avoided.
2021 ACC Guideline on Managing ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
The new ACC guideline provides information to clinicians on the management of atherosclerotic cardiovascular disease risk reduction in patients with persistent hypertriglyceridemia.
LDL-C and CV Health Dependent on Age and Specified Endpoint
The researchers wanted to determine the value of LDL-C as a risk biomarker for coronary heart disease, atherosclerotic cardiovascular disease, and stroke events and deaths for people stratified by age.
Cholesterol Management Supplement Found to Contain Undeclared Rx Ingredient
Cholestene, a dietary supplement marketed for cholesterol management, has been found to contain a hidden drug ingredient, according to the Food and Drug Administration.
HOPE-3 Trial: Lasting Effect of Rosuvastatin Prevents Major Cardiovascular Events
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Resmetirom Reduces Hepatic Fat, Lipid Levels in Patients With Hypothyroidism and Nonalcoholic Steatohepatitis
Investigators report results from MAESTRO-NAFLD-1, a phase 3, randomized, double-blind, placebo-controlled trial evaluating the effect of treatment with resmetirom in patients with hypothyroidism and nonalcoholic steatohepatitis.
- Loading...
Loading...
Next post in AACE 2021
Loading... 
Loading...